恶性黑色素瘤TIL细胞免疫过继疗法途径的探讨  

Adoptive Immunotherapy Pathway of the Malignent Melanoma with TIL Cell

作　　者：唐佩福[1] 曲国番[1] 王玉学[1] 李平波[2] 周国辉[3] 刘辉[3] 

机构地区：[1]哈尔滨医科大学第三临床医学院 [2]黑龙江省医院 [3]北安市人民医院

出　　处：《黑龙江医学》1999年第3期3-3,共1页Heilongjiang Medical Journal

摘　　要：This paper had reported that 8 patients who suffered who malignent melanoma had received TIL cell injechon at primary and matastasis focuses, and the satisfied result was obtained due to TIL cell had higher anti - tumor specificity thanLAK cell whethr under nicroscope or in clinical aspets.This paper had reported that 8 patients who suffered who malignent melanoma had received TIL cell injechon at primary and matastasis focuses, and the satisfied result was obtained due to TIL cell had higher anti - tumor specificity thanLAK cell whethr under nicroscope or in clinical aspets.

关 键 词：TIL细胞 过继 恶性黑色素瘤 疗法 免疫 途径 

分 类 号：R739[医药卫生—肿瘤] R735[医药卫生—临床医学]